Congressman charged in biotech insider trading case

Republican Congressman Chris Collins (U.S. Government, Public Domain)

Republican Congressman Chris Collins has been charged with securities fraud. The case relates to a failed multiple sclerosis trial that precipitated a 92% drop in the stock price of Australian biotech Innate Immunotherapeutics.

Collins was a member of Innate’s board of directors and held a 17% stake in the biotech. According to prosecutors, Collins learned from Innate’s CEO trial had failed on June 22. Collins replied, “Wow. Makes no sense. How are these results even possible???” before calling his son, Cameron. Prosecutors think Collins told his son about the trial failure, leading to a series of stock sales that enabled Cameron to avoid losses of $570,900 when the news became public.

The information also allegedly spread beyond Cameron. The indictment accuses Cameron of passing news of the trial failure on to four people, one of whom informed three more people. Equipped with this insider knowledge, the group allegedly made trades that saved them almost $200,000 in losses.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Throughout most of this period, Innate’s stock was halted in Australia. However, the stock continued to trade on the U.S. OTC market. All of the Republican congressman’s shares were held in Australia and as such were subject to the halt. Collins is not accused of making trades himself and owned the stock when news of the trial failure wiped millions of dollars off the value of his stake.

Collins surrendered himself to FBI agents and vowed to mount “a vigorous defense in court” against charges he thinks are “meritless.” If convicted on all counts, Collins could be hit with a 150-year prison sentence, according to CNN.

The indictment is part of a larger scandal that has engulfed Collins. The Office of Congressional Ethics published a report (PDF) last year that discussed allegations about Collins’ behavior. The report stated Collins may have shared nonpublic material about Innate, purchased discounted stock offered to him because of his position in Congress and told an NIH employee to meet with the biotech.

Suggested Articles

An FDA panel voted against clearance for Neuronix's transcranial magnetic stimulation device, which targets the brain’s memory and learning centers.

A toilet seat monitoring system aims to spot the signs of heart failure in the privacy of the home, with the goal of lowering hospital readmissions.

The proceeds will push its lead asset, repotrectinib, into phase 2 studies and to advance a pair of earlier-stage programs in advanced solid tumors.